Search research articles
Contact Us
Filters
Showing results (151-160 of 236) with videos related to
Page
of 24
Sort By:
The Journal of Experimental Medicine
|
June 18, 2003
B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism
Xingluo Liu, Jian Xin Gao, Jing Wen, et al.
Cancer Immunology Research
|
January 14, 2025
PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells
Kyle R Cron, Ayelet Sivan, Keston Aquino-Michaels, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
July 21, 2007
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases
Ping Yu, Youjin Lee, Yang Wang, et al.
Nature Immunology
|
October 10, 2006
T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha
Yuanyuan Zha, Reinhard Marks, Allen W Ho, et al.
Melanoma Research
|
December 16, 2020
Novel response to neoadjuvant anti-PD1 therapy for a patient with retrocaval melanotic schwannoma
Charles C Vining, Phillip J Hsu, Aaron Miller, et al.
Journal for Immunotherapy of Cancer
|
July 17, 2021
Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma
Riyue Bao, Stefani Spranger, Kyle Hernandez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2004
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies
Todd M Zimmerman, Helena Harlin, Olatoyosi M Odenike, et al.
Investigational New Drugs
|
March 4, 2006
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma
Amy C Peterson, Helena Harlin, Theodore Karrison, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
August 2, 2007
Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics
Michael B Atkins, David Carbone, George Coukos, et al.
Journal for Immunotherapy of Cancer
|
May 16, 2014
A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma
Daniel M Geynisman, Yuanyuan Zha, Rangesh Kunnavakkam, et al.
Page
of 24
Search research articles
Search
Showing results (151-160 of 236) with videos related to
Sort By:
Page
of 24
The Journal of Experimental Medicine
|
June 18, 2003
B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism
Xingluo Liu, Jian Xin Gao, Jing Wen, et al.
Cancer Immunology Research
|
January 14, 2025
PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells
Kyle R Cron, Ayelet Sivan, Keston Aquino-Michaels, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
July 21, 2007
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases
Ping Yu, Youjin Lee, Yang Wang, et al.
Nature Immunology
|
October 10, 2006
T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha
Yuanyuan Zha, Reinhard Marks, Allen W Ho, et al.
Melanoma Research
|
December 16, 2020
Novel response to neoadjuvant anti-PD1 therapy for a patient with retrocaval melanotic schwannoma
Charles C Vining, Phillip J Hsu, Aaron Miller, et al.
Journal for Immunotherapy of Cancer
|
July 17, 2021
Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma
Riyue Bao, Stefani Spranger, Kyle Hernandez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2004
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies
Todd M Zimmerman, Helena Harlin, Olatoyosi M Odenike, et al.
Investigational New Drugs
|
March 4, 2006
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma
Amy C Peterson, Helena Harlin, Theodore Karrison, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
August 2, 2007
Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics
Michael B Atkins, David Carbone, George Coukos, et al.
Journal for Immunotherapy of Cancer
|
May 16, 2014
A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma
Daniel M Geynisman, Yuanyuan Zha, Rangesh Kunnavakkam, et al.
Page
of 24